TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

https://ca.finance.yahoo.com/news/tscan-therapeutics-host-virtual-kol-110000808.html

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will host a virtual key opinion leader (KOL) event, to discuss highlights from its presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting as well as its solid tumor program on Thursday, May 19, 2022, at 4:30 p.m. ET.

The event will provide an in-depth review of the oral and poster presentations related to solid tumor TCR-T therapy candidates, TSC-200-A02 for HPV16, and TSC-204-C07 for MAGE-A1, as well as TScan’s approach to potentially overcome antigen heterogeneity and HLA loss with multiplexed TCR-T. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to [e-mail].

Featured speakers include:

Kai Wucherpfennig, M.D., Ph.D. Chair, Cancer Immunology and Virology and Director, Center for Cancer Immunology Research at the Dana-Farber Cancer Institute, Professor of Neurology, Brigham and Women’s Hospital and Harvard Medical School, and Associate Member, Broad Institute of MIT and Harvard

David Southwell, President and Chief Executive Officer, TScan Therapeutics

Gavin MacBeath, Ph.D., Chief Scientific Officer, TScan Therapeutics

Shrikanta Chattopadhyay, M.D., M.M.Sc., Vice President of Medical, TScan Therapeutics

Registration for the live event can be found here. A replay will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.